Jump to content

What are you buying today?


LowIQinvestor

Recommended Posts

I bought some $95 $IYR puts expiring in January 2025. I expect to lose 100% on these and will use the tax loss in '24 or '25 depending on how things are in December. It hedges some of my REIT exposure after a nice run. I don't think these puts are particularly cheap or anything like that...

 

 

Link to comment
Share on other sites

6 hours ago, StevieV said:

 

No surprise to you, but I think $OWL in the 16s is attractive.  My best guess is that they fall a bit short of their $1/share dividend goal for next year, but I think they'll get to at least something like 92 or 96 cents.  That's a 5-6% yield for next year for a company with very healthy growth, significant "permanent" capital, mostly steady fee, and a decent variety of strategies.

 

Completely agreed. I couldn't care less about $1 in 2025, but if I have an ~5% forward yield and it's able to continue to grow at double digits for 5-10 years, I find that pretty attractive. At least for an alt asset manager. I'm a pretty big fan of the OWL business model and the emphasis on FRE over carry, and I think this should help it trade at a higher multiple. 

 

The most comparable models are BX, BAM, and ARES. And ARES is the most comparable in terms of emphasis on private credit. All of these trade at a richer value, have lower growth, and lower dividend yields than OWL. I'd expect that if OWL avoid a major misstep that this valuation gap will likely close over a period of time, and hopefully will be earning significantly higher FRE/dividends in 3-5 years. 

 

Obviously I love APO/KKR/BX/ARES, but I really think OWL has the most upside at these levels. 

 

 

EDIT: 

 

Just pointing out that all of the major alts (APO, BX, KKR, BAM, CG, ARES, etc.) have made deals to manage insurance AUM, and it appears that OWL is trying to break into the market as well. I think the smaller scale of OWL sets up some really great growth tailwinds as it won't take nearly as much to move the needle in increasing AUM/FRE/DE. 

 

Also, I'm not normally a huge believer in empire builders, but I'm excited about all the tuck in acquisitions that OWL has been pulling off to scale up its credit business. Also I love the general partner business, and I think this has helped OWL identify attractive acquisition targets in addition to being a great source of FRE in itself. 

Edited by Red Lion
Link to comment
Share on other sites

2 hours ago, Dinar said:

Bought Glenveagh.  So @changegonnacome, if it works out, I will owe you a barrel of Guinness or Jamieson/Red Spot.  Made it roughly a 4% position.  That Irish stamp duty at 1% is annoying.

 

Its a deal!

 

And totally hear you on the stamp duty......the UK and Ireland are literally punching themselves in the face from a capital markets point of view attaching stamp duty to share purchases

Link to comment
Share on other sites

2 hours ago, cubsfan said:

 

More RTO 

Perhaps it’s me, but management seems clueless on how to turnaround the US Terminex business. First the CEO was talking about search optimization, then improve employee retention to improve customer retention. Both didn’t work even though “initial results were promising”. Now they are saying that costs were too high because they had employee working weekends which of course lead to higher cost due to overtime pay etc. That was done to squeeze out more revenue yet growth has been dropping all along and sits at 1%.

 

I think management need to go here or progress seems unlikely. ROL has none of the issues and has ~8% organic growth, so it’s not the market or consumer, it’s lack of execution for Rentokil in the US.

Link to comment
Share on other sites

1 hour ago, Spekulatius said:

Perhaps it’s me, but management seems clueless on how to turnaround the US Terminex business. First the CEO was talking about search optimization, then improve employee retention to improve customer retention. Both didn’t work even though “initial results were promising”. Now they are saying that costs were too high because they had employee working weekends which of course lead to higher cost due to overtime pay etc. That was done to squeeze out more revenue yet growth has been dropping all along and sits at 1%.

 

I think management need to go here or progress seems unlikely. ROL has none of the issues and has ~8% organic growth, so it’s not the market or consumer, it’s lack of execution for Rentokil in the US.

 

I can't argue with your criticism. The Terminex acqusition has been a rough one - employee retention has been a real problem. So yeah, it may end up with new management if they can't fix it. Fundamentally, RTO is a dominate business (along with Orkin) that should be earning higher returns once back office systems and duplicate systems are consolidated. It's all about route density and scale. The disparity between Orkin valuation & RTO is much too great.

 

No much excited about the residentail business, but the commercial business is much larger and very lucrative.  The non-US business ought to grow in the 5+% range with developing markets.

 

RTO has been a rollup machine and good with acquisitions - this one was big and difficult.

 

There's been some discussion of RTO here as well:

 

https://thecobf.com/forum/topic/20901-your-largest-equity-buy-in-the-last-three-months-islong-term-buys-mostly/page/6/#comment-579309

 

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...